Disease-modifying drug reduces brain protein plaques in Alzheimer patients

Madely Health Headlines Commentary for March 1, 2010


Neuroimaging technique shows potential of bapineuzumab treatment and might be useful in assessing other drugs for Alzheimer’s Disease


11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Send a Comment